<DOC>
	<DOCNO>NCT01849276</DOCNO>
	<brief_summary>The purpose study determine metformin combination cytarabine safe effective . Participants research study acute myeloid leukemia ( AML ) come back initial treatment go away initial therapy.There evidence metformin directly kill leukemia cell . Laboratory data also show combination metformin cytarabine efficient agent alone kill leukemia cell laboratory .</brief_summary>
	<brief_title>Metformin+Cytarabine Treatment Relapsed/Refractory AML</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) metformin ( metformin hydrochloride ) combination cytarabine relapsed/refractory AML . II . Define dose limit toxicity ( DLT ) metformin combination cytarabine relapsed/refractory AML . SECONDARY OBJECTIVES : I. Remission rate . II . Overall survival ( OS ) . III . Disease-free survival ( DFS ) . IV . Length remission . OUTLINE : This dose-escalation study metformin hydrochloride combination Cytarabine . Patients receive metformin hydrochloride orally ( PO ) twice daily ( BID ) day 1-15 cytarabine intravenously ( IV ) 3 hour BID day 4-10 . After completion study treatment , patient follow every 3 month 2 year every 6 month 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients relapsed/refractory disease must morphologic proof ( bone marrow aspirate , smear touch prep bone marrow biopsy ) AML &gt; = 10 % blast within two week ( 14 day ) prior initiation therapy All immunophenotype cytogenetic/molecular group eligible participation except acute promyelocytic leukemia ( APL ) ( proven presence promyelocytic leukemia/retinoic acid receptor alpha [ PMLRARÎ± ] ) Patients must demonstrate one following : Relapse first complete remission Refractory conventional induction chemotherapy ( failure respond 1 cycle daunorubicin cytarabine ) reinduction Patients previously untreated AML candidate unable receive anthracyclines , document AML &gt; = 20 % blast within one week prior enrollment Patients chronic myelogenous leukemia ( CML ) myeloid blast crisis eligible disease fail respond , and/or intolerant , available tyrosine kinase inhibitor ( TKIs ) Serum total direct bilirubin = &lt; upper limit normal ( ULN ) Serum creatinine &lt; 1.4 mg/dl female &lt; 1.5 mg/dl male , creatinine clearance &gt; 60 mL/min Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) /serum glutamic pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; ULN Bicarbonate within normal range hospital lab ( 2432 mmol/L ) Patients must exhibit Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Females childbearing potential sexually active male must agree use accepted effective method contraception study Childbearing potential define woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : Has NOT undergone hysterectomy bilateral oophorectomy ; OR Has NOT naturally postmenopausal least 12 consecutive month ( i.e . menses time precede 12 consecutive month ) Patients history central nervous system ( CNS ) leukemia eligible symptomatic current CNS involvement If CNS involvement know prior enrollment identify subsequently , treat accordingly Patients may receive therapy malignancy , long complete therapy least 6 month prior study entry deem life expectancy least 2 year regard malignancy All patient must give sign , informed consent prior registration study Patients receive chemotherapy radiotherapy within 4 week prior enrollment NOT eligible participation The exception patient refractory conventional initial induction chemotherapy ( = &lt; 2 course ) first radiation ( 1 course ) ; patient must morphologic proof ( bone marrow aspirate , smear , touch prep marrow biopsy ) AML &gt; 10 % blast within 2 week prior initiation study therapy ; last dose cytotoxic therapy ( NOT include hydrea , allow ) must give &gt; = 14 day prior initiation study therapy Patients history diabetes mellitus ( DM ) treat metformin NOT eligible participation Patients pregnant breast feed NOT eligible participation due lack knowledge regard effect drug fetus breast feeding Patients intercurrent organ damage medical problem would prohibit therapy NOT eligible participation Patients active , uncontrolled infection NOT eligible participation Patients receive therapy another active malignancy NOT eligible participation The exception squamous cell carcinoma basal cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>